Mammoth Biosciences

Edit info

Founded: 2018

Location: Brisbane, CA

Employee range: 11 - 50

Clinical stage: RD

Therapy area: Multiple diagnostics

Drug types: INF, ONC

Lead product: Undisclosed

Funding: $150M D Sep 2021; $45M C Sep 2021; $45M Jan 2020; $23M A Aug 2018

mammoth.bio

linkedin.com

job board

Drug notes:

Undisclosed programs RD undisclosed

About:

Mammoth Biosciences is developing novel CRISPR applications for disease detection, research and biodefense. CRISPR-Cas systems are commonly associated with gene-editing yet they possess potential for many other applications. Mammoth is using their CRISPR-based detection platform, DETECTR, to develop a search engine for biology. This works by identifying CRISPR nucleases that can find a defined gene sequence that activates its nuclease activity, which can then be used to generate a signal. This approach has great potential for searching for the presence of specific nucleic acid sequences that are indicative of disease. Mammoth’s approach is rapid and scalable and offers access to disease detection that can be used in hospitals and homes.